A phase 1/2 trial of CRB-601 monoclonal antibody in advanced solid tumours, run by Corbus Pharmaceuticals Inc., now recruiting.
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. is a phase 1/2 interventional study registered as NCT06603844 by Corbus Pharmaceuticals Inc., with 156 participants planned, started 2024-12-04 and due to reach its primary completion in 2026-11-01. Interventions recorded: CRB-601 monoclonal antibody and Anti-PD-1 monoclonal antibody.
Shares Corbus Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Corbus Pharmaceuticals and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.